China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011.
First Quarter 2011 Highlights
- Revenue increased 20% to $18.1 million from $15.1 million in the first quarter of 2010.
- Cashflow from operations rose 23% to $1.4 million from $1.1 million in first quarter of 2010.
- Gross profit grew 12% to $6.9 million from $6.1 million in the first quarter of 2010.
- Net income, excluding the impact of change in fair value of derivative liability, increased 3% to $4.4 million, compared $4.3 million in the first quarter of 2010.
"In the first quarter of 2011 we achieved solid sales growth primarily due to strong performances by our Digestive Diseases and Anti-Viro product categories. We continue to face moderate pricing pressure across several of our product categories during the quarter, but we expect gross margin and revenue to benefit from anticipated launches of Candesartan and Rosuvastatin in the seasonally strong second half of the year," said Ms. Zhilin Li, China Pharma's Chairman and CEO. "In addition to the expected launch of these two higher margin products later in 2011, we continue to advance our novel cephalosporin-based combination antibiotic through Phase II clinical trials. Commercializing exciting new drugs like this, along with first-to-market generic medicines, is an important part of our strategy to enhance China Pharma's growth and profitability."
First Quarter 2011 Results
Revenues for the quarter ended March 31, 2011 were $18.1 million, up 20% from revenues of $15.1 million for the quarter ended March 31, 2010, reflecting higher sales across all of the Company's product categories led by growth in the Digestive Diseases and Anti-Viro Infection & Respiratory ("Anti-Viro") categories.
The Digestive Diseases product group was the Company's fastest growing revenue category in the first quarter of 2011, with sales increasing 53% to $2.6 million from $1.7 million in the first quarter of 2010. The strong performance of the Digestive Diseases product group primarily reflects continued robust sales of Omeprazole, the Company's generic gastroesophageal reflux disease drug, and Tiopronin, a drug prescribed for treatment of acute Hepatitis B and drug-induced liver damage.
Revenue from the Anti-Viro product category grew 31% to $7.1 million in the quarter ending March 31, 2011, from $5.4 million in the first quarter of 2010. We saw year-over-year sales growth in nearly all products within the Anti-Viro category.
Revenue from the Other product category increased 15% to $3.1 million in the first quarter of 2011 from $2.7 million in the same period last year, driven by strong sales of Vitamin B6.
The CNS Cerebral & Cardio Vascular ("CNS") product group generated revenue of $5.4 million in the first quarter of 2011, roughly flat compared to revenue of $5.3 million in the first quarter of 2010. The Company expects significantly improved future sales growth and profitability in this category upon launch of Candesartan and Rosuvastatin, both of which are CNS products.
Gross profit for the quarter ended March 31, 2011 was $6.9 million, up 12% from gross profit of $6.1 million in the same period of 2010. Gross margin decreased to 37.9% in the first quarter of 2011 from 40.6% in the first quarter of 2010, reflecting pricing pressure across product lines, with the exception of the Digestive Diseases category. The Company estimates that the new tax and surcharges that became applicable recently accounted for approximately 0.8% of the decline in overall margin.
Gross margin for the Digestive Diseases product group increased to 48.4% in the first quarter of 2011 from 47.5% in the same period last year. Anti-Viro gross margin declined slightly to 27.5% in the first quarter of 2011 from 28.6% in the same period last year. Gross margin for the Other product category fell more sharply to 44.9% in the first quarter of 2011 from 49.7% in the same period last year, primarily reflecting strong sales of Vitamin B6, which is on the Essential Drug List and generates lower margin than the category average. CNS product gross margin decreased slightly to 45.3% in the first quarter of 2011 from 45.8% in the same period last year.
Selling, general and administrative expenses in the first quarter of 2011 were $1.5 million, or 8.4% of sales, compared to $1.2 million, or 8.2% of sales, in the same period of 2010. For the quarter ended March 31, 2011, the Company's bad debt expense was $9,428, compared to bad debt expense of $70,906 in the same period of 2010.
Operating income was $5.3 million in the first quarter of 2011, up 11% from $4.8 million in the first quarter of 2010.
For the quarter ended March 31, 2011, the Company paid income tax at a rate of approximately 14%. Income tax expense for the first quarter of 2011 was $0.9 million, compared to $0.5 million for the same period last year. The Company obtained "National High-Tech Enterprise" status from the PRC government in the fourth quarter of 2010. With this designation, the Company is entitled to a preferential tax rate of 15% for the next three years (2011 to 2013), which is notably lower than the statutory income tax rate of 25%.
Net income for the first quarter of 2011 was $5.1 million, or $0.12 per basic and diluted share, compared to $4.9 million, or $0.11 per basic and diluted share, in the first quarter of 2010. Excluding the effect of change in fair value of derivative warrant liability, adjusted non-GAAP net income in the first quarter of 2011 was $4.4 million, or $0.10 per diluted share, compared to $4.3 million, or $0.10 per diluted share, in the first quarter of 2010.
As of March 31, 2011, the Company had cash and cash equivalents of $3.8 million compared to $3.7 million as of December 31, 2010.
Working capital increased to $84 million at March 31, 2011 from $79 million at December 31, 2010. The current ratio rose to 7.6 times at March 31, 2011 from 7.2 times at December 31, 2010.
Accounts receivable balance rose to $64 million at the end of the first quarter of 2011 from $62 million at the end 2010. The Company's management team continues to be sharply focused on improving accounts receivable collection and expects to make further progress in the quarters to come.
For the quarter ended March 31, 2011, cash flow from operating activities was $1.4 million, as compared to $1.1 million in the first quarter of 2010.
"In 2011, we anticipate adding new higher-margin revenue streams to our upcoming new products, which should help offset pockets of margin pressure coming from higher raw material costs and more competitive pricing due to government reform policies. Overall we are very optimistic that we have the right mix of products and pipeline opportunities to position China Pharma to benefit from China's unprecedented $124 billion healthcare reform program," said Ms. Li. "We believe our success in 2011 and beyond will be defined by our high-quality manufacturing facilities and promising pipeline, strong distribution relationships, and commercialization expertise."
As of March 31, 2011, China Pharma had nine pipeline drugs in different stages of active development. The development of three of such products is highlighted below:
- The Company completed clinical trials of Candesartan, a front-line drug therapy for the treatment of hypertension. The Company has completed all testing procedures and currently awaits final SFDA production approval.
- The Company completed clinical trials of Rosuvastatin, a generic form of Crestor, in December 2010 and has submitted an application for SFDA production approval.
- The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in September 2010. Phase I of the clinical trials focused on the study of clinical pharmacology as well as the evaluation of safety on the human body, while observing tolerance and pharmacokinetics to provide support for dosage and drug delivery design. The Company has entered Phase II clinical trials for this drug.
China Pharma Holdings, Inc.